Fig 4. Allograft survival.
(A) allograft survival based on ≤24% tacrolimus (Tac) intra-patient variability (IPV) vs. >24% Tac IPV of cases and controls combined, (B) Allograft survival of c-aABMR cases based on ≤24% Tac IPV vs. >24%.
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.